Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Implementing Long-Acting Cabotegravir Plus Rilpivirine for HIV Treatment: System-Level Considerations

This podcast episode features an international panel discussion on clinic-level considerations for incorporating long-acting ART into the HIV treatment paradigm.
person default
Yvonne Gilleece, MB BCh, BAO
Cristina Mussini, MD
Babafemi Taiwo, MBBS
Darrell H. S. Tan, MD, FRCPC, PhD
Released: August 2, 2022

In this episode, an international expert panel shares their thoughts on key considerations at the operational level for incorporating long-acting injectable antiretroviral therapy into the HIV treatment armamentarium. Topics include the duration of injection appointments in real-world settings, managing additional patient volume/workload (particularly the key role of nurses), and preventing and addressing planned and unplanned missed doses. Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including:

  • Key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience
  • Long-acting HIV pre-exposure prophylaxis
  • What is still needed in long-acting HIV care to further address patient needs and inequities across subgroups

Information on this Educational Activity


Yvonne Gilleece, MB BCh, BAO

Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom

Yvonne Gilleece, MB, BCh, BAO: educational meetings: ViiV; advisor: Gilead Sciences, ViiV; conference sponsorship: Gilead Sciences.
Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases

Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, Janssen, MSD, Pfizer, Roche, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.
Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: Gilead Sciences, Johnson & Johnson, ViiV Healthcare.
Darrell H. S. Tan, MD, FRCPC, PhD

Associate Professor
Division of Infectious Diseases
University of Toronto
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada

Darrell H. S. Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead Sciences, GlaxoSmithKline.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings